pre-IPO PHARMA

COMPANY OVERVIEW

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.7hillspharma.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


May 22, 2023

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding


Aug 1, 2022

7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease


Jun 9, 2022

7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies


Mar 8, 2022

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma


Nov 1, 2021

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines


For More Press Releases


Google Analytics Alternative